356 related articles for article (PubMed ID: 19075702)
21. [Transthyretin-its function and pathogenesis].
Ando Y
Rinsho Byori; 2006 May; 54(5):497-502. PubMed ID: 16789420
[TBL] [Abstract][Full Text] [Related]
22. CSP-1103 (CHF5074) stabilizes human transthyretin in healthy human subjects.
Qiang L; Guan Y; Li X; Liu L; Mu Y; Sugano A; Takaoka Y; Sakaeda T; Imbimbo BP; Yamamura KI; Jin S; Li Z
Amyloid; 2017 Mar; 24(1):42-51. PubMed ID: 28393633
[TBL] [Abstract][Full Text] [Related]
23. Repurposing Benzbromarone for Familial Amyloid Polyneuropathy: A New Transthyretin Tetramer Stabilizer.
Cotrina EY; Oliveira Â; Leite JP; Llop J; Gales L; Quintana J; Cardoso I; Arsequell G
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32998442
[TBL] [Abstract][Full Text] [Related]
24. [Pathogenesis and therapy for transthyretin related amyloidosis].
Ando Y; Jono H
Rinsho Byori; 2008 Feb; 56(2):114-20. PubMed ID: 18402051
[TBL] [Abstract][Full Text] [Related]
25. The flavonoid luteolin, but not luteolin-7-O-glucoside, prevents a transthyretin mediated toxic response.
Iakovleva I; Begum A; Pokrzywa M; Walfridsson M; Sauer-Eriksson AE; Olofsson A
PLoS One; 2015; 10(5):e0128222. PubMed ID: 26020516
[TBL] [Abstract][Full Text] [Related]
26. Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis.
Coelho T; Merlini G; Bulawa CE; Fleming JA; Judge DP; Kelly JW; Maurer MS; Planté-Bordeneuve V; Labaudinière R; Mundayat R; Riley S; Lombardo I; Huertas P
Neurol Ther; 2016 Jun; 5(1):1-25. PubMed ID: 26894299
[TBL] [Abstract][Full Text] [Related]
27. [Cerebral amyloid angiopathy with familial transthyretin-derived oculoleptomeningeal amyloidosis].
Ikeda SI
Brain Nerve; 2013 Jul; 65(7):831-42. PubMed ID: 23832986
[TBL] [Abstract][Full Text] [Related]
28. [Transthyretin-related amyloidotic cardiomyopathy: looking for the etiological treatment].
Longhi S; Gagliardi C; Milandri A; Manuzzi L; Rapezzi C
G Ital Cardiol (Rome); 2014 May; 15(5):293-300. PubMed ID: 25002169
[TBL] [Abstract][Full Text] [Related]
29. Cardiac Amyloidosis Due to Transthyretin Protein: A Review.
Ruberg FL; Maurer MS
JAMA; 2024 Mar; 331(9):778-791. PubMed ID: 38441582
[TBL] [Abstract][Full Text] [Related]
30. Methods to evaluate the inhibition of TTR fibrillogenesis induced by small ligands.
Arsequell G; Planas A
Curr Med Chem; 2012; 19(15):2343-55. PubMed ID: 22471983
[TBL] [Abstract][Full Text] [Related]
31. Amyloid disease prevention by transthyretin native state complexation with carborane derivatives lacking cyclooxygenase inhibition.
Julius RL; Hawthorne MF
Drug News Perspect; 2008 Jun; 21(5):258-66. PubMed ID: 18596990
[TBL] [Abstract][Full Text] [Related]
32. The transthyretin amyloidoses: advances in therapy.
Dubrey S; Ackermann E; Gillmore J
Postgrad Med J; 2015 Aug; 91(1078):439-48. PubMed ID: 26048914
[TBL] [Abstract][Full Text] [Related]
33. Transthyretin amyloidosis: a tale of weak interactions.
Saraiva MJ
FEBS Lett; 2001 Jun; 498(2-3):201-3. PubMed ID: 11412857
[TBL] [Abstract][Full Text] [Related]
34. Small transthyretin (TTR) ligands as possible therapeutic agents in TTR amyloidoses.
Almeida MR; Gales L; Damas AM; Cardoso I; Saraiva MJ
Curr Drug Targets CNS Neurol Disord; 2005 Oct; 4(5):587-96. PubMed ID: 16266291
[TBL] [Abstract][Full Text] [Related]
35. Transthyretin cardiac amyloidoses in older North Americans.
Dharmarajan K; Maurer MS
J Am Geriatr Soc; 2012 Apr; 60(4):765-74. PubMed ID: 22329529
[TBL] [Abstract][Full Text] [Related]
36. Clusterin regulates transthyretin amyloidosis.
Lee KW; Lee DH; Son H; Kim YS; Park JY; Roh GS; Kim HJ; Kang SS; Cho GJ; Choi WS
Biochem Biophys Res Commun; 2009 Oct; 388(2):256-60. PubMed ID: 19664600
[TBL] [Abstract][Full Text] [Related]
37. A substructure combination strategy to create potent and selective transthyretin kinetic stabilizers that prevent amyloidogenesis and cytotoxicity.
Choi S; Reixach N; Connelly S; Johnson SM; Wilson IA; Kelly JW
J Am Chem Soc; 2010 Feb; 132(4):1359-70. PubMed ID: 20043671
[TBL] [Abstract][Full Text] [Related]
38. D18G transthyretin is monomeric, aggregation prone, and not detectable in plasma and cerebrospinal fluid: a prescription for central nervous system amyloidosis?
Hammarström P; Sekijima Y; White JT; Wiseman RL; Lim A; Costello CE; Altland K; Garzuly F; Budka H; Kelly JW
Biochemistry; 2003 Jun; 42(22):6656-63. PubMed ID: 12779320
[TBL] [Abstract][Full Text] [Related]
39. Age-related oxidative modifications of transthyretin modulate its amyloidogenicity.
Zhao L; Buxbaum JN; Reixach N
Biochemistry; 2013 Mar; 52(11):1913-26. PubMed ID: 23414091
[TBL] [Abstract][Full Text] [Related]
40. R104H may suppress transthyretin amyloidogenesis by thermodynamic stabilization, but not by the kinetic mechanism characterizing T119 interallelic trans-suppression.
Sekijima Y; Dendle MT; Wiseman RL; White JT; D'Haeze W; Kelly JW
Amyloid; 2006 Jun; 13(2):57-66. PubMed ID: 16911959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
